Steven Lichtman
Stock Analyst at Oppenheimer
(2.92)
# 1,473
Out of 5,130 analysts
72
Total ratings
38.46%
Success rate
12.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $21.70 | +1.38% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $289.04 | +26.28% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $97.64 | +28.02% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $67.40 | +51.34% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $92.85 | +45.40% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.85 | +105.13% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $80.13 | +37.28% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $97.53 | -3.62% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $8.84 | +635.29% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $23.11 | -52.40% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $9.86 | +21.70% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $86.38 | +0.72% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.49 | +616.92% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $367.54 | -21.64% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $112.92 | -7.01% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $22.12 | +578.12% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $83.45 | +1.86% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $21.70
Upside: +1.38%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $289.04
Upside: +26.28%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $97.64
Upside: +28.02%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $67.40
Upside: +51.34%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $92.85
Upside: +45.40%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.85
Upside: +105.13%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $80.13
Upside: +37.28%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $97.53
Upside: -3.62%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $8.84
Upside: +635.29%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $23.11
Upside: -52.40%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.86
Upside: +21.70%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $86.38
Upside: +0.72%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.49
Upside: +616.92%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $367.54
Upside: -21.64%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $112.92
Upside: -7.01%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $22.12
Upside: +578.12%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $83.45
Upside: +1.86%